Q1: 2026-05-06 Earnings Summary

EPS of $0.54 beats by $0.00

|

Revenue of

$492.32M

(1.83% Y/Y)

misses by $6.88M

Qiagen N.V. ( QGEN ) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing May 7, 2026 9:30 AM EDT

Company Participants

Domenica Martorana - Associate Director of Global Investor Relations

Thierry Bernard - CEO, MD & Member of Management Board

Nadia Aelbrecht

Nitin Sood - Senior VP & Head of Product Portfolio & Innovation

Parampal Deol

Conference Call Participants

Riccardo Triunfo

Presentation

Domenica Martorana

Associate Director of Global Investor Relations

Welcome to our spotlight session. Today, it's all about QuantiFERON. And in the next hour, you will learn more about our strategic priorities and the latest developments. But before we start, let's have a closer look into the legal disclaimer.

As with any investor event, this presentation includes a safe harbor statement.…